Pay in 4 interest-free payments of $5.14 Learn more
Ships within 48 hours · Estimated delivery Sep 12 - Sep 17
Why rely on chance
Some protocols use subcutaneous injections a tiny needle just under the skin, similar to insulin
Side-by-Side Comparison Parameter Receptors Cagrilintide AMY1R/2R/3R + CTR Semaglutide GLP-1R Tirzepatide GLP-1R + GIPR Retatrutide GLP-1R + GIPR + Glucagon-R Parameter Half-life Cagrilintide ~7-8 days Semaglutide ~7 days Tirzepatide ~5 days Retatrutide ~6 days Parameter Dosing frequency Cagrilintide Once weekly Semaglutide Once weekly Tirzepatide Once weekly Retatrutide Once weekly Parameter Max studied dose Cagrilintide 4.5 mg/week (mono) Semaglutide 2.4 mg/week Tirzepatide 15 mg/week Retatrutide 12 mg/week Parameter Peak monotherapy weight loss Cagrilintide 11.8% at 68 wk Semaglutide 14.9-17% at 68 wk Tirzepatide 22.5% at 72 wk Retatrutide ~24% at 48 wk Parameter FDA status (June 2026) Cagrilintide Investigational Semaglutide Approved (2021) Tirzepatide Approved (2023) Retatrutide Investigational Parameter HbA1c reduction (T2D) Cagrilintide ~0.9 pp mono
Its major patents have recently expired: in the US and Europe, the patent ran out at the end of 2023, after which generic versions appeared in 2024
Tirzepatide, on the other hand, is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist
Time constraints are another major issue
US$ 26.58
US$ 29.25
US$ 28.25
US$ 29.30
US$ 21.89
US$ 25.45
US$ 19.99
US$ 28.74
